

Note: This document has been translated from the Japanese original for reference purposes only, and is not intended to solicit an investment in the Company or similar activity. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect, or any other forms of damages arising from the translation.



March 11, 2026
Fuji Pharma Co., Ltd.

Notice Regarding Completion of Exercise of 2nd Series Stock Acquisition Rights Issued by Third-Party Allotment

We would like to announce that the 2nd Series of Stock Acquisition Rights (hereinafter referred to as the "Stock Acquisition Rights") issued by our company on August 5, 2024, with Nomura Securities Co., Ltd. as the allottee, have been fully exercised as of March 11, 2026.

We hereby notify you as follows.

1. Details of the Stock Acquisition Rights

(1) Name of Stock Acquisition Rights	Fuji Pharma Co., Ltd. 2nd Series of Stock Acquisition Rights
(2) Number of Stock Acquisition Rights Issued	16,500 units
(3) Number of Exercise of the Stock Acquisition Rights	16,500 units
(4) Number of Remaining Stock Acquisition Rights	0 units
(5) Amount of funds raised through the exercise of Stock Acquisition Rights	3,300,000,000 yen
(6) Allottee of the Stock Acquisition Rights	Nomura Securities Co., Ltd.
(7) Issue Date of the Stock Acquisition Rights	August 5, 2024

2. Total Number of Issued Shares and Amount of Capital (March 11, 2026)

(1) Issued shares	26,541,100 shares
(2) Amount of capital	5,555,919,505 yen

For details regarding the issuance of the stock acquisition rights, please refer to the "Notice of Issuance of 1st to 3rd Series Stock Acquisition Rights via Third-Party Allotment" disclosed on July 18, 2024.

For further information, contact

Fuji Pharma Co., Ltd.

Corporate Communication Section, Corporate Planning Department, Corporate Strategy Division

fsk_ir@fujipharma.jp